Literature DB >> 23895622

Assessment of tenascin-C levels in ventricular noncompaction/hypertrabeculation patients: a cross-sectional study.

Hatice Betul Erer1, Tolga Sinan Guvenc, Ahu Sarbay Kemik, Hale Yilmaz, Seref Kul, Servet Altay, Dilaver Oz, Gonul Zeren, Ahmet Ekmekci, Aycan Esen Zencirci, Nurten Sayar, Mehmet Eren.   

Abstract

PURPOSE: Ventricular noncompaction/hypertrabeculation (NC/HT) is a rare form of congenital cardiomyopathy. We aimed to investigate the presence of serum tenascin-C (TN-C) in adult patients with NC/HT and evaluate its value. METHODS AND
RESULTS: Serum TN-C levels were measured by ELISA in 50 NC/HT patients both with/without systolic dysfunction and in 23 normal controls. Systolic dysfunction was defined as ejection fraction (EF) ≤ 40. Mann-Whitney U-test and ROC curve analysis were done. Of 49 NC/HT patients, 24 (49%) patients had systolic dysfunction (mean age 36 ± 15) and 25 patients (51%) had normal systolic function (mean age 36 ± 17). The ages between groups were not different. The mean levels of serum TN-C in patients with or without systolic dysfunction were 26 ± 10 ng/mL and 26 ± 8 ng/mL respectively, compared to normal controls, 7 ± 2 ng/mL (P < 0.001). No significance was observed between 2 groups of NC/HT patients regarding TN-C levels (P = 0.8). The ROC curve analysis revealed that a TN-C value of 11.7 ng/mL identified patients with NC/HT with 100% sensitivity and specifity.
CONCLUSION: High serum TN-C levels are present in adult NC/HT cardiomyopathy even when left ventricular systolic function remains normal. Also, serum TN-C levels could be regarded as a candidate biomarker in the diagnosis of NC/HT which needs to be tested in larger prospective studies.
© 2013, Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiomyopathy; hypertrabeculation; noncompaction; tenascin-C

Mesh:

Substances:

Year:  2013        PMID: 23895622     DOI: 10.1111/echo.12328

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  4 in total

Review 1.  Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.

Authors:  Marcus Franz; Christian Jung; Alexander Lauten; Hans R Figulla; Alexander Berndt
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

Review 2.  Non-compaction cardiomyopathy: prevalence, prognosis, pathoetiology, genetics, and risk of cardioembolism.

Authors:  Pedro Carrilho-Ferreira; Ana G Almeida; Fausto J Pinto
Journal:  Curr Heart Fail Rep       Date:  2014-12

3.  Non-Compaction Cardiomyopathy and Multiple Sclerosis: Associated or Independent Diseases? A Case Report.

Authors:  Juan Manuel Muñoz Moreno; Carlos Holguin Palacios; Carlos Lobato Jeri; Sebastian Reyes Villanes; Wilson Peralta Ramos; Miguel Reyes Rocha
Journal:  Front Cardiovasc Med       Date:  2022-05-06

Review 4.  Tenascin-C in Heart Diseases-The Role of Inflammation.

Authors:  Kyoko Imanaka-Yoshida
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.